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Context
Despite the treatments available for type 2 diabetes, about two-thirds of
these patients die from associated heart disease or stroke.1 Approval of the
ﬁrst glucagon-like peptide-1 agonist (GLP-1), exenatide, by the FDA in
2005 generated an expectation that the clinical outcomes in type 2 diabetes
would be improved. However, we still do not have deﬁnitive evidence that
exenatide does this, although a clinical trial to determine this, the Exenatide
Study of Cardiovascular Even Lowering (EXSCEL) trial, is under way.2
Subsequently, other GLP-1 agonists, including liraglutide, have also been
approved and used for 10 years without clinical outcome data.3 Recently,
the results of Liraglutide Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcomes Results (LEADER) have been published.
Methods
LEADER was a double-blinded, randomised, multinational, non-
inferiority clinical trial comparing liraglutide and placebo in persons
with type 2 diabetes and high cardiovascular risk (eg, prior myocardial
infarction). The non-inferiority margin was chosen as 1.30 for the upper
boundary of the 95% CI of the HR. Patients had to have an HbA1c of
≥7%, with or without other treatment for type 2 diabetes. Only patients
who were able to adhere to the injection regimen (liraglutide or placebo
subcutaneously) in a 2-week run in were randomised. The primary com-
posite outcome was the ﬁrst occurrence of death from cardiovascular
disease, non-fatal myocardial infraction or non-fatal stroke.
Findings
After a median follow-up of 3.8 years, the primary outcome had occurred
in fewer patients in the liraglutide group (608 of 4668, 13.0%) than in
the placebo group (694 of 4672, 14.9%) (HR, 0.87; 95% CI 0.78 to 0.97;
p<0.001 for non-inferiority; p=0.01 for superiority), and this was due to
a reduction in cardiovascular deaths. Microvascular events were also sig-
niﬁcantly reduced by liraglutide. At baseline, the mean HbA1C was 8.7%,
and at the end of the study, the difference was ∼0.4%. During the study,
more medications (antidiabetic, diuretics and lipid-lowering) were given
to patients in the placebo group than in the liraglutide group. Weight
loss was 2.3 kg with liraglutide. The main adverse effects of liraglutide
were gastrointestinal, and there were 9.1% discontinuations in the lira-
glutide group (vs 7.3% in the placebo group). Pancreatic carcinoma
occurred in 5 patients in the placebo group and 13 in the liraglutide
group (p=0.06).
Commentary
The main reason that patients with type 2 are encouraged to take antidia-
betic medications is to reduce clinical outcomes such as cardiovascular
deaths, rather than surrogate outcomes such as HbA1c. Thus, clinical
trials with clinical outcomes are extremely important and should be
timely. Although it has taken 11 years since approval by the FDA for the
use of liraglutide to the publication of LEADER, I welcome the ﬁnding
that liraglutide does reduce cardiovascular deaths, but still there is a
question why we had to wait so long for this vital information. Also, I
note that there are some limitations and unanswered questions in
LEADER. First, as LEADER only included patients who were adherent to
subcutaneous injections, the results can only be applied to this cohort,
and not to all patients with type 2 diabetes. Second, the level of β
blocker use was higher at baseline with liraglutide, and the introduction
of diuretics and antidiabetic medications (other than GLP-1 agonists) was
higher in the placebo group than the liraglutide group during the study,
and it is not known whether these differences contributed to the out-
comes. Third, the reduction in HbA1c with liraglutide was modest, and
other factors, for example, weight loss, may have contributed to the
beneﬁt observed with liraglutide. Probably the most important ﬁndings
were that HbA1c levels remained high, and the reductions in cardiovas-
cular deaths were modest with liraglutide. This suggests that there is
room for further improvements in the treatment of type 2 diabetes.
Implications for practice
In addition to liraglutide, the GLP-1 agonist semaglutide has also
recently been shown to reduce cardiovascular outcomes in patients with
type 2 diabetes and high cardiovascular risk,4 whereas lixisenatide did
not reduce these outcomes in persons with type 2 diabetes and acute cor-
onary syndromes.5 Thus, liraglutide and semaglutide should presently be
considered the leaders among the GLP-1 agonists to treat patients with
type 2 diabetes and high cardiovascular risk. Unless cardiovascular out-
comes are established, the other GLP-1 agonists (exenatide, albiglutide,
dulaglutide) should be the second choice.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
References
1. Khardori R. Diabetes mellitus, type 2. http://emedicine.medscape.com/article/
117853-overview (accessed 28 Sep 2016).
2. Holman RR, Bethel MA, George J, et al. Rationale and design of the Exenatide study
of cardiovascular event lowering (EXSCEL) trial. Am Heart J 2016;174:103–10.
3. Doggrell SA. Are we waiting too long for the cardiovascular outcome trials with the
glucagon-like peptide-1 receptor agonists? Expert Opin Drug Safety 2015;14:801–5.
4. Marso SP, Bain SC, Consoli A, et al. Semiglutide and cardiovascular outcomes in
patients with type 2 diabetes. N Engl J Med Q12016. Published Online First.
5. Pfeffer MA, Clagget B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes
and acute coronary syndromes. N Engl J Med 2015;373:2247–457.
Evid Based Med Month 2016 | volume 0 | number 0 | 1
Therapeutics/Prevention
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
